Equities
  • Price (EUR)5.75
  • Today's Change0.00 / 0.00%
  • Shares traded451.00
  • 1 Year change+38.22%
  • Beta0.7105
Data delayed at least 15 minutes, as of Feb 18 2026 07:14 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Cash flow in CNYView more

In 2024, cash reserves at KeyMed Biosciences Inc fell by 432.62m. Cash Flow from Financing totalled 283.90m or 66.31% of revenues. In addition the company used 789.63m for operations while cash from investing totalled 67.71m.
Cash flow per share-0.6931
Price/Cash flow per share--
Book value per share12.10
Tangible book value per share12.07
More ▼

Balance sheet in CNYView more

KeyMed Biosciences Inc has a Debt to Total Capital ratio of 21.45%, a higher figure than the previous year's 13.84%.
Current ratio3.95
Quick ratio3.74
Total debt/total equity0.273
Total debt/total capital0.2145
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.